Publications While At Healthpartners
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial
Diabetes, Obesity & Metabolism.
Efficacy and safety of LixiLan vs. insulin glargine according to baseline characteristics in patients with type 2 diabetes from the LixiLan-L Trial [abstract 1018-P]
Map of science